Literature DB >> 27297319

Increased rates of intensive care unit admission in patients with Mycoplasma pneumoniae: a retrospective study.

T Khoury1, S Sviri2, A A Rmeileh1, A Nubani1, A Abutbul2, S Hoss1, P V van Heerden2, A E Bayya2, C Hidalgo-Grass3, A E Moses3, R Nir-Paz4.   

Abstract

Mycoplasma pneumoniae is a leading cause of respiratory disease. In the Intensive Care Unit (ICU) setting M. pneumoniae is not considered a common pathogen. In 2010-13 an epidemic of M. pneumoniae-associated infections was reported and we observed an increase of M. pneumoniae patients admitted to ICU. We analysed the cohort of all M. pneumoniae-positive patients' admissions during 2007 to 2012 at the Hadassah-Hebrew University Medical Centre (a 1100-bed tertiary medical centre). Mycoplasma pneumoniae diagnosis was made routinely using PCR on throat swabs and other respiratory samples. Clinical parameters were retrospectively extracted. We identified 416 M. pneumoniae-infected patients; of which 68 (16.3%) were admitted to ICU. Of these, 48% (173/416) were paediatric patients with ICU admission rate of 4.6% (8/173). In the 19- to 65-year age group ICU admission rate rose to 18% (32/171), and to 38.8% (28/72) for patients older than 65 years. The mean APACHE II score on ICU admission was 20, with a median ICU stay of 7 days, and median hospital stay of 11.5 days. Of the ICU-admitted patients, 54.4% (37/68) were mechanically ventilated upon ICU admission. In 38.2% (26/68), additional pathogens were identified mostly later as secondary pathogens. A concomitant cardiac manifestation occurred in up to 36.8% (25/68) of patients. The in-hospital mortality was 29.4% (20/68) and correlated with APACHE II score. Contrary to previous reports, a substantial proportion (16.3%) of our M. pneumoniae-infected patients required ICU admission, especially in the adult population, with significant morbidity and mortality.
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease severity; Intensive care unit; Mortality; Mycoplasma pneumoniae; Pneumonia

Mesh:

Year:  2016        PMID: 27297319     DOI: 10.1016/j.cmi.2016.05.028

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  12 in total

Review 1.  Molecular Tools for Typing Mycoplasma pneumoniae and Mycoplasma genitalium.

Authors:  Roger Dumke
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

2.  Adjunctive corticosteroid therapy for inpatients with Mycoplasma pneumoniae pneumonia.

Authors:  Masato Tashiro; Kiyohide Fushimi; Kei Kawano; Takahiro Takazono; Tomomi Saijo; Kazuko Yamamoto; Shintaro Kurihara; Yoshifumi Imamura; Taiga Miyazaki; Katsunori Yanagihara; Hiroshi Mukae; Koichi Izumikawa
Journal:  BMC Pulm Med       Date:  2017-12-29       Impact factor: 3.317

3.  Mycoplasma Pneumoniae Pneumonia: Walking Pneumonia Can Cripple the Susceptible.

Authors:  Bharat Bajantri; Omesh Toolsie; Sindhaghatta Venkatram; Gilda Diaz-Fuentes
Journal:  J Clin Med Res       Date:  2018-10-30

4.  Early diagnosis and appropriate respiratory support for Mycoplasma pneumoniae pneumonia associated acute respiratory distress syndrome in young and adult patients: a case series from two centers.

Authors:  Lin Ding; Yu Zhao; Xuyan Li; Rui Wang; Ying Li; Xiao Tang; Bing Sun; Hangyong He
Journal:  BMC Infect Dis       Date:  2020-05-24       Impact factor: 3.090

5.  Characteristics and Outcome of Severe Mycoplasma pneumoniae Pneumonia Admitted to PICU in Shanghai: A Retrospective Cohort Study.

Authors:  Yiping Zhou; Yijun Shan; Yun Cui; Jingyi Shi; Fei Wang; Huijie Miao; Chunxia Wang; Yucai Zhang
Journal:  Crit Care Explor       Date:  2021-03-23

6.  Fluoroquinolone and no risk of Achilles-tendinopathy in childhood pneumonia under eight years of age-a nationwide retrospective cohort.

Authors:  Yunsun Kim; Gun Woo Park; Sangyoung Kim; Hui Jeong Moon; Sungho Won; Wankyo Chung; Hyeon-Jong Yang
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

Review 7.  Mycoplasma pneumoniae: A Potentially Severe Infection.

Authors:  Bharat Bajantri; Sindhaghatta Venkatram; Gilda Diaz-Fuentes
Journal:  J Clin Med Res       Date:  2018-06-04

8.  Epidemiological characterization of respiratory tract infections caused by Mycoplasma pneumoniae during epidemic and post-epidemic periods in North China, from 2011 to 2016.

Authors:  Jiuxin Qu; Chunxia Yang; Fang Bao; Shuyan Chen; Li Gu; Bin Cao
Journal:  BMC Infect Dis       Date:  2018-07-17       Impact factor: 3.090

9.  Severe atypical pneumonia in critically ill patients: a retrospective multicenter study.

Authors:  S Valade; L Biard; V Lemiale; L Argaud; F Pène; L Papazian; F Bruneel; A Seguin; A Kouatchet; J Oziel; S Rouleau; N Bele; K Razazi; O Lesieur; F Boissier; B Megarbane; N Bigé; N Brulé; A S Moreau; A Lautrette; O Peyrony; P Perez; J Mayaux; E Azoulay
Journal:  Ann Intensive Care       Date:  2018-08-13       Impact factor: 6.925

10.  Lipid moieties of Mycoplasma pneumoniae lipoproteins are the causative factor of vaccine-enhanced disease.

Authors:  Arlind B Mara; Tyler D Gavitt; Edan R Tulman; Steven J Geary; Steven M Szczepanek
Journal:  NPJ Vaccines       Date:  2020-04-08       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.